We are interested in strategic partnership discussions to support further development of our programs including MN-221 and MN-166. We would consider both partnership (i.e. licensing agreement, profit-sharing agreement, etc.) and investment opportunities. Although our non-core compounds do not have clinical trials ongoing at this time, we are pursuing partnership opportunities to continue their development.
If you would like to discuss any of our compounds as potential partnership or investment opportunities, please contact our Business Development department by completing the form below: